- $1.99bn
- $1.88bn
- $237.22m
- 79
- 12
- 56
- 47
Annual income statement for Vericel, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 124 | 156 | 164 | 198 | 237 |
| Cost of Revenue | |||||
| Gross Profit | 84.2 | 106 | 110 | 136 | 172 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 122 | 164 | 181 | 204 | 233 |
| Operating Profit | 2.37 | -7.85 | -17.1 | -6.46 | 4.52 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 3.04 | -7.58 | -16 | -2.37 | 10.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 2.86 | -7.47 | -16.7 | -3.18 | 10.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 2.86 | -7.47 | -16.7 | -3.18 | 10.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 2.86 | -7.47 | -16.7 | -3.18 | 10.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.061 | -0.161 | -0.355 | -0.067 | 0.201 |